Population Pharmacokinetics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran, in Atrial Fibrillation Patients Receiving Long-Term Anticoagulation Therapy

By Bååthe Sofie  

Clinical Pharmacokinetics, Vol. 45, Iss. 8, 2006-01 ,pp. : 803-819

Adis International

Access to resources Recommend Favorite

Influence of Severe Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Ximelagatran and Subcutaneous Melagatran

By Eriksson U.G.  

Clinical Pharmacokinetics, Vol. 42, Iss. 8, 2003-01 ,pp. : 743-753

Adis International

Access to resources Recommend Favorite

Pharmacokinetics, Preliminary Efficacy and Safety of Subcutaneous Melagatran and Oral Ximelagatran: A Multicentre Study of Thromboprophylaxis in Elective Abdominal Surgery

By Bergqvist D.  

Clinical Drug Investigation, Vol. 24, Iss. 3, 2004-01 ,pp. : 127-136

Adis International

Access to resources Recommend Favorite

Ximelagatran/Melagatran: A Review of its Use in the Prevention of Venous Thromboembolism in Orthopaedic Surgery

By Evans H.C.   Perry C.M.   Faulds D.  

Drugs, Vol. 64, Iss. 6, 2004-01 ,pp. : 649-678

Adis International

Access to resources Recommend Favorite

Comparable Pharmacokinetics and Pharmacodynamics of Melagatran in Japanese and Caucasian Volunteers after Oral Administration of the Direct Thrombin Inhibitor Ximelagatran

By Wernevik Linda C.  

Clinical Pharmacokinetics, Vol. 45, Iss. 1, 2006-01 ,pp. : 85-94

Adis International

Access to resources Recommend Favorite